Back to All Topics
Myostatin
Research Article
3 min read
WADA Regulations on Myostatin Inhibitors
Current anti-doping regulations specifically addressing myostatin inhibition.
Introduction
WADA maintains specific prohibitions against myostatin inhibitors and related approaches.
Current WADA Classifications
Prohibited Categories
| Category | Description | Myostatin Relevance |
|---|---|---|
| S4 | Hormone and metabolic modulators | Myostatin inhibitors |
| M3 | Gene and cell doping | Gene therapy approaches |
| S0 | Non-approved substances | Research peptides |
Specific Substances
| Substance | Category | Status |
|---|---|---|
| Myostatin-inhibiting antibodies | S4 | Prohibited |
| Follistatin | S4/M3 | Prohibited |
| ACE-031 | S4 | Prohibited |
| CRISPR for myostatin | M3 | Prohibited |
Detection Challenges
Current Methods
| Method | Target | Effectiveness |
|---|---|---|
| Antibody detection | Specific compounds | Limited |
| Biomarker profiles | Secondary effects | Developing |
| Genetic analysis | Gene doping | Research |
Limitations
| Challenge | Impact |
|---|---|
| Novel compounds | May escape detection |
| Gene modifications | Very difficult |
| Natural variation | Confounding factor |
| Rapid evolution | Constant updates needed |
Recent WADA Updates
Prohibited List Evolution
| Year | Change | Significance |
|---|---|---|
| Annual | Regular updates | Stays current |
| Emerging threats | Proactive additions | Anticipatory |
| Gene doping emphasis | Growing focus | Future-proofing |
Enforcement Reality
Testing Practicalities
| Factor | Reality |
|---|---|
| Sample collection | Standard protocols |
| Analysis capability | Varies by substance |
| False positives | Concern with biomarkers |
| Cost | Limits comprehensive testing |
Consequences
| Offense | Standard Sanction |
|---|---|
| First positive | 4 years |
| Second | 8 years to lifetime |
| Trafficking | 4-10 years minimum |
Future Regulatory Directions
Anticipated Developments
| Area | Expected Direction |
|---|---|
| Biomarker panels | Enhanced |
| Genetic testing | Expanded |
| AI-assisted detection | Implemented |
| International coordination | Strengthened |
Gene Doping Focus
| Concern | Response |
|---|---|
| Undetectable modification | Research priority |
| Germline changes | Major concern |
| Detection research | Significant investment |
| Athlete education | Prevention focus |
Athlete Responsibilities
Under WADA Code
| Responsibility | Requirement |
|---|---|
| Strict liability | Athlete responsible for body |
| Declaration | TUE requirements |
| Whereabouts | Testing availability |
| Knowledge | Stay informed |
Practical Guidance
| Action | Importance |
|---|---|
| Avoid all myostatin inhibitors | Absolute |
| Verify supplements | Critical |
| Report approaches | Whistleblower protections |
| Stay updated | Annual list changes |
Conclusion
WADA maintains comprehensive prohibition of myostatin inhibitors with ongoing detection development.
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.